Why the study?
Does quinapril or irbesartan alter neutral endopeptidase activity and bradykinin concentrations in rats with induced myocardial infarction?
Does quinapril or irbesartan alter neutral endopeptidase activity and bradykinin concentrations in rats with induced myocardial infarction?
AT1 receptor blockade with irbesartan increases cardiac bradykinin via inhibition of neutral endopeptidase after myocardial infarction in rats, suggesting a mechanism for its cardioprotective effects.
No takes yet. Share an insight, caveat, or question.
May explain irbesartan's post-MI benefits via NEP inhibition in rats; hypothesis-generating and should not change practice.
Walther et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: